Seebri Breezhaler

Seebri Breezhaler Uses, Dosage, Side Effects, Food Interaction and all others data.

Seebri Breezhaler is a long-acting, specific antimuscarinic agent, in clinical medicine often called an anticholinergic. It has a similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, inhibition of M3-receptors at the smooth muscle results in relaxation. The high potency and slow receptor dissociation found its clinical correlate in significant and long-acting bronchodilation in patients with COPD.

Seebri Breezhaler is a quaternary ammonium compound that is one of the most commonly prescribed long acting muscarinic antagonists. Seebri Breezhaler slowly dissociated from muscarinic receptors, leading to a long duration of action. It has a wider therapeutic index than other anticholinergic medications, such as tiotropium. Patients should be counselled regarding the risk of worsening urinary retention, risk of overheating, and transient blurred vision.

Trade Name Seebri Breezhaler
Availability Prescription only
Generic Glycopyrronium
Glycopyrronium Other Names Glicopirronio, Glycopyrrolate ion, Glycopyrronium, Glycopyrronium ion
Related Drugs Botox, Drysol, onabotulinumtoxinA, Qbrexza, Hypercare
Weight 50mcg, , 50µg
Type Inhalation Capsule, Capsule, Powder Inhaler
Formula C19H28NO3
Weight Average: 318.4305
Monoisotopic: 318.206918767
Protein binding

Glycopyrronium is 38-44% protein bound in plasma. It is bound to serum albumin, alpha-1-acid glycoprotein, as well as other plasma proteins that have not been identified in literature.

Groups Approved, Investigational, Vet approved
Therapeutic Class Bronchodilator
Manufacturer Novartis (bangladesh) Ltd, , Novartis Pharmaceuticals Uk Ltd, Novartis Pharma Ag, Novartis Indonesia
Available Country Bangladesh, United Kingdom, Canada, Australia, Saudi Arabia, United States, Netherlands, Indonesia,
Last Updated: September 19, 2023 at 7:00 am
Seebri Breezhaler
Seebri Breezhaler

How Seebri Breezhaler works

Seebri Breezhaler is a muscarinic antagonist with the highest affinity for M1 receptors, followed by M3, M2/M4, and M5.

Muscarinic receptors M1 to M4 are found in the lung, although M3 is predominantly responsible for bronchoconstriction and airway secretions. Secretions from salivary and sweat glands, as well as gastric acid secretions, are also predominantly mediated by the M3 receptor. Salivary and gastric acid secretions are also partially mediated by the M1 receptor. Antagonism of these receptors decreases the volume of their respective secretions, and in the case of the gastrointestinal system, reduces the acidity of the stomach.

In the cardiovascular system, muscarinic receptors M1 to M5 are all present, however the function of M5 has not been described in literature. Under normal circumstances, stimulation of the vagal nerve lowers the heart rate, potentially leading to intraoperative bradycardia. Studies in mice suggest that this stimulation is predominantly mediated by the M3 receptor, and mutant knockout mice are not susceptible to these effects.

Dosage

Seebri Breezhaler dosage

The recommended dosage of Seebri Breezhaler is the inhalation of the contents of one capsule once daily with the ConviHaler device at the same time of day.

Side Effects

Inhaled medicines may cause inhalation-induced bronchospasm, dehydration, dry mouth, constipation, dizziness, insomnia, skin and subcutaneous tissue disorders, immune system disorders.

Toxicity

Patients presenting with an overdose typically present with flushing, hyperthermia, tachycardia, ileus, urinary retention, loss of ocular accommodation, light sensitivity, mydriasis, nausea, vomiting, dizziness, light headedness, and obstipation. Patients should be treated with symptomatic and supportive therapy, which may include the use of catheters for urinary retention, cardiovascular support, airway maintenance, ventilation, or neostigmine.

The oral LD50 in mice is 570 mg/kg, and in rats is 709 mg/kg. The intraperitoneal LD50 in mice is 90 mg/kg, and in rats is 196 mg/kg.

Precaution

Seebri Breezhaler, as a once-daily maintenance bronchodilator, should not be used for the initial treatment of acute episodes of bronchospasm, i.e. rescue therapy. Immediate hypersensitivity reactions may occur after administration of Seebri Breezhaler inhalation powder. As with other anticholinergic drugs, Seebri Breezhaler should be used with caution in patients with narrow-angle glaucoma, prostatic hyperplasia or bladder-neck obstruction.

Interaction

Although no formal drug interaction studies have been performed, Seebri Breezhaler inhalation powder has been used concomitantly with other drugs, commonly used in the treatment of COPD, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids without clinical evidence of drug interactions.

Food Interaction

  • Take with or without food. The absorption is unaffected by food.

Volume of Distribution

The mean volume of distribution in patients aged 1-14 years old is 1.3-1.8 L/kg, with a range of 0.7-3.9 L/kg. The volume of distribution in adults aged 60-75 years is 0.42 ± 0.22 L/kg.

Elimination Route

In adults, a 66 mg topical dose of glycopyrronium reaches a Cmax of 0.08 ± 0.04 ng/mL, with a Tmax of 1 hour, and an AUC0-24 of 0.88 ± 0.57 h*ng/mL.

Inhaled glycopyrronium is approximately 40% bioavailable. A 25 µg inhaled solution reaches a Cmax of 34.5 pg/mL, with a Tmax of 0-inf of 255 h*pg/mL.

An 8 µg/kg intramuscular dose reaches a Cmax of 3.47 ± 1.48 µg/L, with a Tmax of 27.48 ± 6.12 minutes, and an AUC of 6.64 ± 2.33 h*g/L.

Oral glycopyrronium has highly variable pharmacokinetics, reaching a mean Cmax of 0.318 ng/mL, a Tmax of 3.1 hours, and an AUC0-24 of 1.74 h*ng/mL.

Half Life

The half life after inhalation is approximately 33-53 hours. The mean half life of a 6 µg/kg intravenous dose is 0.83 ± 0.27 hours. The mean half life of oral glycopyrronium is 3.0 hours.

Clearance

A 6 µg/kg intravenous dose has a clearance of 0.54 ± 0.14 L/kg/h. An oral solution has a clearance of 5.28-38.95 L/h/kg in healthy adults and 8.07-25.65 L/h/kg in patients with cerebral palsy.

Elimination Route

85% of an intravenous dose was recovered in the urine, with 12 >80% of the recovered dose is the unchanged parent drug. The remainder is recovered as the inactive M9 metabolite.

Pregnancy & Breastfeeding use

There is a limited amount of data from the use of Seebri Breezhaler in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity at clinically relevant doses. Seebri Breezhaler should not be used in pregnant or nursing women unless the expected benefit outweighs any possible risk to the unborn child or the infant.

Contraindication

Hypersensitivity to the active substance or to any of the excipients.

Acute Overdose

High doses of Seebri Breezhaler may lead to anticholinergic signs and symptoms. However, there were no systemic anticholinergic adverse effects following a single inhaled dose of up to 150 micrograms Seebri Breezhaler in healthy volunteers.

Storage Condition

Should be stored at temperature not exceeding 25ºC but do not freeze. Should be stored in cool and dry place, protected from light.

Innovators Monograph

You find simplified version here Seebri Breezhaler

Seebri Breezhaler contains Glycopyrronium see full prescribing information from innovator Seebri Breezhaler Monograph, Seebri Breezhaler MSDS, Seebri Breezhaler FDA label

*** Taking medicines without doctor's advice can cause long-term problems.
Share